Mike Quirk joined Sage in 2014, initially helping to build translational science and establish Sage’s NMDA receptor modulator platform and over the last 9 years has taken on increasing roles of responsibility. In his role as Chief Scientific Officer, Mike leads Sage’s Research, Nonclinical Development, and Clinical Pharmacology teams supporting programs from early discovery through commercialization. Prior to joining Sage, Mike was a Director within the Neuroscience Innovative Medicines group at AstraZeneca where he worked on a variety of programs within psychiatry and neurology. With over 15 years of diverse industry experience, Mike has been critically involved, as both scientific and program lead, in over 10 programs that have made the transition from preclinical to clinical development.

Mike is a trained neurophysiologist and translational scientist with over 25 peer reviewed manuscripts in the areas of neurotransmission, memory formation and retrieval, and neural mechanisms of decision-making and goal-directed behavior. He holds both a S.B degree in Cognitive Science and a Ph.D. in Systems Neuroscience from the Massachusetts Institute of Technology (MIT) and completed his post-doctoral training at the Cold Spring Harbor Laboratory in New York.